REGENERATIVE CAPACITY OF THE CD4+ T CELLS IN AIDS

描述（改编自研究者摘要）：本研究的目标 该项目是为了了解再生和免疫生物学 HIV-1感染受试者中CD 4 + T细胞的能力，并探索 对免疫恢复的影响 考虑到艾滋病毒1型感染的破坏性， 在CD 4阳性T细胞上，研究者假设再生的 随着疾病的发展，能力和技能将逐渐减少。 或者，如果CD 4阳性T细胞具有取之不尽的能力， 再生后，可以维持扩增能力和库。 区分这些可能性具有强烈的含义， 当有效的抗逆转录病毒治疗时， 制定的。 在目前的项目中，第一个具体目标包括 设计用于确定CD 4阳性T细胞扩增能力的实验 来自HIV-1感染不同阶段患者的细胞。 受试者 再分为高病毒载量组和低病毒载量组。 再生 能力将与CD 4 + T细胞的再生能力进行比较 来自未感染的受试者和感染的长期非进展者。 在 第二个目标，实验将检查免疫生物学的剧目， CD 4 + T细胞的功能，因为它们通过重复的有丝分裂 分裂 保护所有细胞的免疫生物学功能 分裂预示着免疫恢复的程度和持续时间 病毒复制停止后。 在第三个具体目标中， 将检查CD 4 T细胞计数极低的受试者亚组， 确定再生和免疫生物学能力之前和之后， 他们接受了有效的抗逆转录病毒疗法。 这些研究报告将 纵向评估。 这将提供证据证明是否停止 病毒感染破坏将允许具有高 如果新的CD 4阳性T细胞被激活， 胸腺衍生的 具体目的四、临床意义 将确定再生能力。

DESCRIPTION (adapted from the investigator's abstract): The goal of this project is to gain understanding of the regeneration and immunobiologic capacities of the CD4+ T cells in HIV-1 infected subjects, and to explore their implication for immune recovery. Given the ravages of HIV-1 infection on CD4 positive T cells, the investigator hypothesized that the regenerative capacity and repertoire will progressively diminish as the disease advances. Alternatively, if CD4 positive T cells have an inexhaustible ability to regenerate, the expansion capacity and repertoire may be maintained. Distinguishing between these possibilities have a strong implication as to the extent of immunologic recovery when effective anti-retroviral therapy is instituted. In the current project, the first specific aims include experiments designed to determine the expansion capacity of CD4 positive T cells from patients at various stages of HIV-1 infection. Subjects are sub-divided into groups with high and low viral loads. The regenerative capacity will be compared with the regenerative capacity of CD4+ T cells from uninfected subjects and infected, long term non-progressors. In the second aim, experiments will examine the immunobiological repertoire and function of CD4+ T cells as they advance through repetitive mitotic divisions. Preservation of the immunobiologic function through all cell divisions bode well for both the extent and duration of immunologic recovery after virus replication is halted. In the third specific aim, a selected sub-groups of subjects with very low CD4 T cell counts will be examined to determine the regenerative and immunobiologic capacities before and after they have received potent anti-retroviral therapy. These studies will be assessed longitudinally. This will provide evidence as to whether stopping the ravages of viral infection will permit gradual return of cells with high regenerative capacity as might be expected if new CD4 positive T cells are thymic derived. In specific aim four, the clinical significance of the regenerative capacity will be determined.